OK Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021
Share
OK Biotech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 309.09 million compared to TWD 341.93 million a year ago. Net income was TWD 15.29 million compared to TWD 26.39 million a year ago. Basic earnings per share from continuing operations was TWD 0.16 compared to TWD 0.3 a year ago. Diluted earnings per share from continuing operations was TWD 0.15 compared to TWD 0.29 a year ago. Basic earnings per share was TWD 0.16 compared to TWD 0.3 a year ago. Diluted earnings per share was TWD 0.15 compared to TWD 0.29 a year ago.
For the nine months, sales was TWD 905.55 million compared to TWD 1,032.02 million a year ago. Net income was TWD 44.89 million compared to TWD 94.07 million a year ago. Basic earnings per share from continuing operations was TWD 0.48 compared to TWD 1.17 a year ago. Diluted earnings per share from continuing operations was TWD 0.45 compared to TWD 1.1 a year ago. Basic earnings per share was TWD 0.48 compared to TWD 1.17 a year ago. Diluted earnings per share was TWD 0.45 compared to TWD 1.1 a year ago.
OK Biotech Corporation is principally engaged in the manufacture and distribution of medical supplies and products. The Company primarily provides household medical glucose meters and disposable glucose testing strips. Its products are applied in the testing and monitoring of glucose value for diabetes patients, hospitals, clinic doctors and nurses, among others. The Company distributes its products principally in Taiwan, other Asian markets and the United States.